Approaches for the development of antiviral compounds: The case of hepatitis C virus

Handbook of Experimental Pharmacology

Volumn 189, Issue , 2009, Pages 25-51

  Schinazi, Raymond F ^a   Coats, Steven J ^b   Bassit, Leda C ^b   Lennerstrand, Johan ^b   Nettles, James H ^b   Hurwitz, Selwyn J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4' CHLORO 4 (4 HYDROXY 1 PIPERIDINYLCARBONYL)BIPHENYL 2 YLMETHOXY] 2 FLUOROPHENYL] 1 CYCLOHEXYL 5 BENZIMIDAZOLECARBOXYLIC ACID; 2 THENOIC ACID; 4' AZIDOCYTIDINE; A 782759; ANTIVIRUS AGENT; ATAZANAVIR; BENZO 1,2,4 THIADIAZINE; BETA DEXTRO 2' DEOXY 2' FLUORO 2' C METHYLCYTIDINE; BETA DEXTRO N HYDROXYCYTIDINE; BL 2021; BOCEPREVIR; CILUPREVIR; MK 0608; NUCLEOSIDE ANALOG; PEGINTERFERON; PROTEINASE INHIBITOR; PSI 6130; R 7128; RIBONUCLEOSIDE DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; VALOPICITABINE; VERTEX; ENZYME INHIBITOR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CARDIOTOXICITY; CELL ASSAY; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS C; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VIRUS GENE; X RAY CRYSTALLOGRAPHY; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61549092835     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79086-0_2     Document Type: Review

References (111)

1. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417-1426
2. Aungst BJ (1999) P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev 39:105-116
3. Balimane PV, Sinko PJ (1999) Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv Drug Deliv Rev 39:183-209
4. Benet LZ, Cummins CL, Wu CY (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9
5. Bilello JA, Bilello PA, Stellrecht K, Leonard J, Norbeck DW, Kempf DJ, Robins T, Drusano GL (1996) Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 40:1491-1497
6. Bio MM, Xu F, Waters M, Williams JM, Savary KA, Cowden CJ, Yang C, Buck E, Song ZJ, Tschaen DM, Volante RP, Reamer RA, Grabowski EJ (2004) Practical synthesis of a potent hepatitis C virus RNA replication inhibitor. J Org Chem 69:6257-6266
7. Biswal BK, Cherney MM, Wang M, Chan L, Yannopoulos CG, Bilimoria D, Nicolas O, Bedard J, James MN (2005) Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by nonnucleoside inhibitors. J Biol Chem 280:18202-18210
8. Biswal BK, Wang M, Cherney MM, Chan L, Yannopoulos CG, Bilimoria D, Bedard J, James MN (2006) Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J Mol Biol 361:33-45
9. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V (2003) Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 19:825-835
10. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL,Mathieu M, De Francesco R, Rey FA (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 96:13034-13039
11. Bressanelli S, Tomei L, Rey FA, De Francesco R (2002) Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 76:3482-3492
12. Burton G, Ku TW, Carr TJ, Kiesow T, Sarisky RT, Lin-Goerke J, Baker A, Earnshaw DL, Hofmann GA, Keenan RM, Dhanak D (2005) Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture. Bioorg Med Chem Lett 15:1553-1556
13. Carroll SS, Olsen DB (2006) Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets (Formerly Current Drug Targets -Infectious) 6:17-29
14. Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ (2006) Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2:183-212
15. Chandra P, Brouwer KL (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21:719-735
16. Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V (2006) Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. J Med Chem 49:995-1005
17. Condon SM, LaPorte MG, Herbertz T (2005) Allosteric inhibitors of hepatitis C NS5B RNAdependent RNA polymerase. Curr Med Chem Anti-Infect Agents 4:99-110
18. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW (2003) A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 36:1585-1592
19. Courcambeck J, Bouzidi M, Perbost R, Jouirou B, Amrani N, Cacoub P, Pepe G, Sabatier JM, Halfon P (2006) Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir Ther 11:847-855
20. D'Abramo CM, Cellai L, Gotte M (2004) Excision of incorporated nucleotide analogue chainterminators can diminish their inhibitory effects on viral RNA-dependent RNA polymerases. J Mol Biol 337:1-14
21. De Clercq E (2007) The design of drugs for HIV and HCV. Nat Rev Drug Discov 6:1001-1018
22. de Mendoza C, Soriano V (2005) The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. Antivir Ther 10 Suppl 2:M109-M115
23. de Mendoza C, Martin-Carbonero L, Barreiro P, de Baar M, Zahonero N, Rodriguez-Novoa S, Benito JM, Gonzalez-Lahoz J, Soriano V (2007) Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. AIDS 21:583-588
24. Deval J, D'Abramo CM, Gotte M (2006) Selective excision of non-obligate chain-terminators by the hepatitis C virus NS5B polymerase. In: 16th international HIV Drug Resistance workshop, Sitges, Spain, June 13-17, 2006. Antivir Ther 11 Suppl 1:S3 (abstract no 1)
25. Di Marco S, Volpari C, Tomei L, Altamura S, Harper S, Narjes F, Koch U, Rowley M, De Francesco R, Migliaccio G, Carfi A (2005) Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 280: 29765-29770
26. Ding Y, Girardet JL, Smith KL, Larson G, Prigaro B, Lai VC, ZhongW,Wu JZ (2005) Parallel synthesis of pteridine derivatives as potent inhibitors for hepatitis C virus NS5B RNA-dependent RNA polymerase. Bioorg Med Chem Lett 15:675-678
27. Ding Y, Girardet JL, Smith KL, Larson G, Prigaro B,Wu JZ, Yao N (2006) Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase. Bioorg Chem 34:26-38
28. Dutartre H, Bussetta C, Boretto J, Canard B (2006) General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues. Antimicrob Agents Chemother 50:4161-4169
29. Elferink RO, Groen AK (2002) Genetic defects in hepatobiliary transport. Biochim Biophys Acta 1586:129-145
30. Failla C, Tomei L, De Francesco R (1994) Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 68:3753-3760
31. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136:288-292
32. Feitelson MA, Larkin JD (2001) New animal models of hepatitis B and C. ILAR J 42:127-138
33. Frassetto L, Thai T, Aggarwal AM, Bucher P, Jacobsen W, Christians U, Benet LZ, Floren LC (2003) Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet 18:114-120
34. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B,McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354:251-260
35. Gerber JB, Kiser JJ (2007) Clinical pharmacology at the 14th CROI. Conference reports by NATAB. http://www.natap.org/2007/CROI/croi 95.htm
36. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R (2004) Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 5:443-462
37. Goudreau N, Cameron DR, Bonneau P, Gorys V, Plouffe C, PoirierM, Lamarre D, Llinas-BrunetM (2004) NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent. J Med Chem 47:123-132
38. Han NI, Lee YS, Choi H, Choi JY, Yun SK, Cho SH, Han JY, Yang JM, Ahn BM, Choi SW, Lee CD, Cha SB, Sun HS, Park DH (2002) PCNA expression and electron microscopic study of acinus-forming hepatocytes in chronic hepatitis B. Korean J Intern Med 17:100-106
39. Herve F, Urien S, Albengres E, Duche JC, Tillement JP (1994) Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet 26:44-58
40. Huang Z, Murray MG, Secrist JA IIIrd (2006) Recent development of therapeutics for chronic HCV infection. Antiviral Res 71:351-362
41. Hurwitz SJ, Schinazi RF (2002) Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. Antiviral Res 56:115-127
42. Hurwitz SJ, Tennant BC, Korba BE, Gerin JL, Schinazi RF (1998) Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans. Antimicrob Agents Chemother 42:2804-2809
43. Hurwitz SJ, Otto MJ, Schinazi RF (2005) Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Antivir Chem Chemother 16:117-127
44. Jones K, Hoggard PG, Khoo S, Maher B, Back DJ (2001) Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. Br J Clin Pharmacol 51:99-102
45. Kim J, Chong Y (2006a) Docking and binding mode analysis of aryl diketoacids (ADK) at the active site of HCV RNA-dependent RNA polymerase. Mol Simul 32:1131-1138
46. Kim J, Chong Y (2006b) Understanding the RNA-specificity of HCV RdRp: implications for anti-HCV drug discovery. Bull Korean Chem Soc 27:59-64
47. Kim MJ, Kao C (2001) Factors regulating template switch in vitro by viral RNA-dependent RNA polymerases: implications for RNA-RNA recombination. Proc Natl Acad Sci USA 98: 4972-4977
48. King JR, Wynn H, Brundage R, Acosta EP (2004) Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 43:291-310
49. Koch U, Narjes F (2006) Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect Disord Drug Targets 6:31-41
50. Koch U, Attenni B, Malancona S, Colarusso S, Conte I, Di Filippo M, Harper S, Pacini B, Giomini C, Thomas S, Incitti I, Tomei L, De Francesco R, Altamura S, Matassa VG, Narjes F (2006) 2-(2-Thienyl)-5,6-dihydroxy-4- carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. J Med Chem 49:1693-1705
51. Kozlov MV, Polyakov KM, Ivanov AV, Filippova SE, Kuzyakin AO, Tunitskaya VL, Kochetkov SN (2006) Hepatitis C virus RNA-dependent RNA polymerase: study on the inhibition mechanism by pyrogallol derivatives. Biochemistry (Moscow) 71:1021-1026
52. Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, Ramachandran C, Amidon GL (2003) Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther 306:778-786
53. LaPlante SR, Llinas-Brunet M (2005) Dynamics and structure-based design of drugs targeting the critical serine protease of the hepatitis C virus -from a peptidic substrate to BILN 2061. Curr Med Chem Anti-Infect Agents 4:111-132
54. Le Pogam S, Jiang WR, Leveque V, Rajyaguru S, Ma H, Kang H, Jiang S, Singer M, Ali S, Klumpp K, Smith D, Symons J, Cammack N, Najera I (2006a) In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349-359
55. Le Pogam S, Kang H, Harris SF, Leveque V, Giannetti AM, Ali S, Jiang WR, Rajyaguru S, Tavares G, Oshiro C, Hendricks T, Klumpp K, Symons J, Browner MF, Cammack N, Najera I (2006b) Selection and characterization of replicon variants dually resistant to thumband palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 80: 6146-6154
56. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6:937-943
57. Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237
58. Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A, Kashuba AD (2004) Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 36:1034-1040
59. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD (2004) In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 279:17508-17514
60. Lin K, Perni RB, Kwong AD, Lin C (2006) VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 50:1813-1822
61. Lohmann V, Korner F, Herian U, Bartenschlager R (1997) Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 71:8416-8428
62. Love RA, Parge HE, Yu X, Hickey MJ, Diehl W, Gao J, Wriggers H, Ekker A, Wang L, Thomson JA, Dragovich PS, Fuhrman SA (2003) Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J Virol 77:7575-7581
63. Manns MP,Wedemeyer H, CornbergM(2006) Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350-1359
64. Marieb NE (2007) Human anatomy and physiology, 7th edn. Pearson/Benjamin Cummings, San Francisco
65. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66:3225-3229
66. Meanwell NA, Belema M, Carini DJ, D'Andrea SV, Kadow JF, Krystal M, Naidu BN, Regueiro-Ren A, Scola PM, Sit SY, Walker MA, Wang T, Yeung KS (2005) Developments in antiviral drug design, discovery and development in 2004. Curr Drug Targets Infect Disord 5:307-400
67. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 4:35-43
68. Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, Ng T, Koev G, Stoll V, Stewart KD, Pratt J, Donner P, Rockway T, Maring C, Molla A (2005) Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 49:4305-4314
69. Moyle GJ, Back D (2001) Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2:105-113
70. Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA (2007) Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 51:503-509
71. Neyts J (2006) Selective inhibitors of hepatitis C virus replication. Antiviral Res 71:363-371
72. Nguyen ML, Nguyen MM, Lee D, Griep AE, Lambert PF (2003) The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 77:6957-6964
73. O'Farrell D, Trowbridge R, Rowlands D, Jager J (2003) Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J Mol Biol 326:1025-1035
74. Olsen DB (2006) Potent nucleoside inhibitors of HCV RNA replication: SAR and other lessons learned. In: 17th international roundtable on nucleosides, nucleotides and nucleic acids, Bern, Switzerland
75. Patel BA, Boudinot FD, Schinazi RF, Gallo JM, Chu CK (1990) Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species. J Pharmacobiodyn 13:206-211
76. Patil SD, Ngo LY, Glue P, Unadkat JD (1998) Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm Res 15:950-952
77. Pauli-Magnus C, Meier PJ (2006) Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44:778-787
78. Pierra C, Benzaria S, Amador A, Moussa A, Mathieu S, Storer R, Gosselin G (2005) Nm 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 24:767-770
79. Prusoff WH (1959) Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta 32:295-296
80. Prusoff WH, Chen MS, Fischer PH, Lin TS, Shiau GT, Schinazi RF, Walker J (1979) Antiviral iodinated pyrimidine deoxyribonucleosides: 5-iodo-2'- deoxyuridine; 5-iodo-2'-deoxycytidine; 5-iodo-5'-amino-2',5'-dideoxyuridine. Pharmacol Ther 7:1-34
81. Ranjith-Kumar CT, Kim YC, Gutshall L, Silverman C, Khandekar S, Sarisky RT, Kao CC (2002) Mechanism of de novo initiation by the hepatitis C virus RNA-dependent RNA polymerase: role of divalent metals. J Virol 76:12513-12525
82. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PL (2006) Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002
83. Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG (2005) Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41:832-835
84. Sagir A, Schmitt M, Dilger K, Haussinger D (2003) Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. Digestion 68:41-48
85. Schinazi RF (1991) Combined therapeutic modalities for viral infections -rationale and clinical potential. In: Chou TC, Rideout DC (eds) Synergism and antagonism in chemotherapy. Academic, Orlando, FL, pp 110-181
86. Shepard CW, Finelli L, AlterMJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567
87. Sheppard GS, Bouska JJ (2005) Why optimize cancer drugs fro ADMET? Drug Discov Today Ther Strateg 2:343-349
88. Shim JH, Hong Z, Wu JZ (2006) Recent patents on nucleoside and nucleotide inhibitors for HCV. Recent Patents Anti-Infect Drug Disc 1:323-331
89. Soars MG, McGinnity DF, Grime K, Riley RJ (2006) The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2-15
90. Stauber RE, Stadlbauer V (2006) Novel approaches for therapy of chronic hepatitis C. J Clin Virol 36:87-94
91. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J (2007) Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73:1573-1581
92. Stuyver LJ, McBrayer TR, Tharnish PM, Hassan AE, Chu CK, Pankiewicz KW, Watanabe KA, Schinazi RF, Otto MJ (2003a) Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J Virol 77:10689-10694
93. Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, Ramesh M, Chu CK, Jordan R, Shi J, Rachakonda S, Watanabe KA, Otto MJ, Schinazi RF (2003b) Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 47:244-254
94. Stuyver LJ, Lostia S, Patterson SE, Clark JL, Watanabe KA, Otto MJ, Pankiewicz KW (2002) Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents. Antivir Chem Chemother 13:345-52
95. Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie MY, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ (2006a) Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-Cmethylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 17:79-87
96. Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie MY, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ (2006b) Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-Cmethylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 17:79-87
97. Tai CL, Chi WK, Chen DS, Hwang LH (1996) The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol 70:8477-8484
98. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA (2006) Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70:28-38
99. Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140:1-22
100. Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, Llinas-Brunet M, Nar H, Lamarre D (2003) Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed Engl 42:1356-1360
101. Urbani A, Bianchi E, Narjes F, Tramontano A, De Francesco R, Steinkuhler C, Pessi A (1997) Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem 272:9204-9209
102. Vermeir M, Annaert P, Mamidi RN, Roymans D, Meuldermans W, Mannens G (2005) Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin Drug Metab Toxicol 1:75-90
103. Wacher VJ, Silverman JA, Zhang Y, Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330
104. Wang M, Ng KK, Cherney MM, Chan L, Yannopoulos CG, Bedard J, Morin N, Nguyen-Ba N, Alaoui-Ismaili MH, Bethell RC, James MN (2003) Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 278:9489-9495
105. Wu JZ, Yao N, Walker M, Hong Z (2005) Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase. Mini Rev Med Chem 5:1103-1112
106. Yamashita T, Kaneko S, Shirota Y, Qin W, Nomura T, Kobayashi K, Murakami S (1998) RNAdependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J Biol Chem 273:15479-15486
107. Yan S, Appleby T, Gunic E, Shim JH, Tasu T, Kim H, Rong F, Chen H, Hamatake R, Wu JZ, Hong Z, Yao N (2007) Isothiazoles as active-site inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett 17:28-33
108. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, De Francesco R, Kuo LC, Chen Z (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 7:837-847
109. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Jr., Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52-60
110. Zhong W, Uss AS, Ferrari E, Lau JY, Hong Z (2000) De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J Virol 74:2017-2022
111. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304